Current Management of Patients with HCV Genotype 2

Treatment landscape for virus hepatitis C (HCV) has continuously evolved in the last 5 years. The current standard of care is a pangenotypic direct-acting antiviral (DAA) regimen including the fixed-dose combination of the NS5B inhibitor sofosbuvir plus the NS5A inhibitor velpatasvir (SOF/VEL), or the combination of the pangenotypic NS3 and NS5 inhibitors glecaprevir and pibrentasvir (Gle/Pib). Sustained virological response (SVR) rates reported with these regimens are higher than 95%, regardless of genotype. The main advantage of a pangenotypic regimen is a reduced risk of treatment failure in case of incorrect genotyping or in the presence of chimera genotype 1–2 virus. Given the pre-existing differences related to the need of extending or intensifying treatment in patients with cirrhosis or Interferon experienced, the advantage of SOF/VEL is SVR rates of 100% in genotype 2 (GT2) patients including treatment naive or experienced and patients with or without cirrhosis. With Gle/Pib SVR of 98% are associated with only 8 weeks of treatment in non-cirrhotic patients.